Reuters reports on how the results of an experimental AIDS vaccine which showed modest potential for preventing infection are leading researchers back “to the drawing board” as they try to better understand how the AIDS vaccine works.
GlaxoSmithKline (GSK) Chief Executive Andrew Witty on Friday announced Brazil has agreed to buy roughly $2.2 billion of the company’s vaccine for pneumococcal disease, Synflorix, for a period of at least eight years, in exchange for a technology transfer, eventually allowing Brazil to manufacture the vaccine itself, the Wall Street Journal reports.
Additional countries are expected to soon announce they will follow in the footsteps of nine developed countries who recently said they would donate H1N1 (swine flu) vaccine supplies to poorer nations, David Nabarro, of the U.N. said Friday, Reuters reports.
Also In Global Health News: News Outlets Explore AIDS Vaccine Research; Chloroquine Resistance Unraveled; Authorities Contest Maternal Mortality Report
News Outlets Focus On Participants In AIDS Vaccine Study, Potential Impact Of AIDS Vaccine The Associated Press examines the role of the Thai participants in the recent clinical trial of an experimental HIV vaccine which showed modest potential for preventing infection. “Nearly 16,000 Thais ignored the false rumors that they…
International drug makers are expected to produce three billion doses of the H1N1 (swine flu) vaccine, “enough for just under half the world’s population,” a WHO official said Thursday, Canwest News Service/Ottawa Citizen reports. “The agency was hoping pharmaceutical companies would be able to make about five billion doses a year, but data collected over the summer led to the revised estimate,” the news service writes.
For the first time, scientists say an investigational vaccine has modest potential for protecting people against HIV infection, the Associated Press reports. “The vaccine â€” a combination of two previously unsuccessful vaccines â€” cut the risk of becoming infected with HIV by … 31 percent in the world’s largest [HIV] vaccine trial of more than 16,000 volunteers in Thailand, researchers announced Thursday in Bangkok,” the news service writes (Marchione/Casey, 9/24).
During the WHO Asia-Pacific regional meeting Monday, WHO Director-General Margaret Chan discussed the organization’s efforts to ensure that poor nations have access to H1N1 vaccines, VOA News reports (Bayron, 9/21). ABC Radio Australia reports Chan is seeking “three billion doses of swine flu vaccine to be made available worldwide, especially in developing countries where it still poses a serious risk” (9/22).
The U.N. this week will request that wealthy nations and development banks donate $1.48 billion to the help developing countries fight H1N1 (swine flu), Bloomberg reports.
The Kenya Ministry of Public Health on Saturday will launch a $1.8 million measles vaccination campaign targeting “1.3 million children who have not been vaccinated against the disease since July 2006,” Business Daily Africa reports. “Measles has become a major public concern in the country and in northern Kenya refugee camps in particular,” as the government has found itself “unable to screen refugees flooding into the country through Kenyaâ€™s porous northern border,” the newspaper writes.
A group of nine countries on Thursday announced they would share H1N1 (swine flu) vaccine supplies with developing nations to protect the world’s poorest from the H1N1 virus, Reuters reports. The U.S. joined Australia, Brazil, France, Italy, New Zealand, Norway, Switzerland, and Britain in the pledge, according to the news service. The new donations add to the 120 million vaccine doses pharmaceutical companies GlaxoSmithKline and Sanofi-Pasteur pledged to WHO.